CLEAR LABELS Act
Official title: A bill to amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information.
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Placed on Senate Legislative Calendar under General Orders. Calendar No. 523.
Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act or the CLEAR LABELS Act
This bill requires drugs and active pharmaceutical ingredients made available in the U.S. market to be labeled with the names and locations of their manufacturers.
Specifically, a finished, packaged drug product must be labeled with the name and place of business of (1) the original manufacturer (or manufacturers) of each active pharmaceutical ingredient; (2) the original manufacturer of the finished drug product; and (3) the packer or distributor, if any. This information must be printed on the product label or made available electronically. Active pharmaceutical ingredients (which are generally sold to manufacturers and researchers, not consumers) must also be labeled with the name and place of business of their original manufacturers.
Under the bill, the original manufacturer is the establishment that conducts the majority of the significant phases of manufacturing to produce the ingredient or product.
The Food and Drug Administration (FDA) has discretion to determine whether a violation of these requirements constitutes misbranding and to assess a civil fine. The FDA must consider certain factors in determining whether to assess a fine, including whether the violator was notified of their noncompliance and was provided an opportunity to correct the violation.
Finally, the FDA must coordinate with U.S. Customs and Border Protection to address any overlap between these requirements and existing requirements for imported drugs.
These provisions take effect five years after the bill is enacted.
- Introduced in Senate Formatted Text PDF Formatted XML
- Reported to Senate Formatted Text PDF Formatted XML
- NATIONAL COMMUNITY PHARMACISTS ASSOCIATION
- THE NICKLES GROUP, LLC
- BIOTECHNOLOGY INNOVATION ORGANIZATION
- THE UNITED STATES PHARMACOPEIAL CONVENTION
- PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
- GSK (FKA GLAXOSMITHKLINE INC.)
Bodies those filers lobbied
- SENATE
- HOUSE OF REPRESENTATIVES
- Health & Human Services, Dept of (HHS)
- Centers For Medicare and Medicaid Services (CMS)
- Food & Drug Administration (FDA)
- Office of Management & Budget (OMB)
- White House Office
- Patent & Trademark Office (PTO)
Cite this page
U.S. Congress. (2026). S. 3788: CLEAR LABELS Act. 119th Congress. Open America. https://openamerica.io/bill/119-S-3788/
"S. 3788: CLEAR LABELS Act." 119th Congress, 2026, Open America, https://openamerica.io/bill/119-S-3788/.
S. 3788, 119th Cong. (2026), https://openamerica.io/bill/119-S-3788/.
[S. 3788: CLEAR LABELS Act](https://openamerica.io/bill/119-S-3788/)